A Randomized Phase II Study of Gemcitabine/Cisplatin With or Without Sorafenib to Evaluate the Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer. MAPS Trial.

Trial Profile

A Randomized Phase II Study of Gemcitabine/Cisplatin With or Without Sorafenib to Evaluate the Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer. MAPS Trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Sorafenib (Primary) ; Cisplatin; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms MAPS
  • Most Recent Events

    • 07 Aug 2012 Actual end date (14 Jun 2009) added as reported by European Clinical Trials Database.
    • 08 Oct 2010 Results presented at the 35th Congress of the European Society for Medical Oncology (ESMO)
    • 06 Jun 2010 Status changed from recruiting to active, no longer recruiting due to presentation of results at 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top